Cargando…

Adjuvant therapy of HER2(+ )breast cancer

Detalles Bibliográficos
Autor principal:	Winer, EP
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284877/ http://dx.doi.org/10.1186/bcr2274

Ejemplares similares

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Adjuvant therapy after preoperative treatment for breast cancer
por: Ciruelos, E
Publicado: (2009)

Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial
por: Rodenhuis, S, et al.
Publicado: (2005)

Herceptin-sensitivity of HER2-transgenic mouse mammary tumors
por: Schwall, RH, et al.
Publicado: (2003)

Update on HER2-directed therapy
por: Slamon, D
Publicado: (2005)

Bisphosphonates in the adjuvant treatment of early breast cancer
por: Gnant, M
Publicado: (2009)

Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer
por: Gijsen, M, et al.
Publicado: (2010)

Molecular mechanisms of resistance to HER2-targeted therapy
por: Esteva, FJ
Publicado: (2009)

Adjuvant therapy in colorectal cancer – studies of the FOGT group
por: Staib, Ludger, et al.
Publicado: (2010)

Adjuvant chemotherapy for operable breast cancer: old vs new schema
por: Valagussa, P, et al.
Publicado: (2005)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2(+ )breast cancer
por: Cortés-Funes, H, et al.
Publicado: (2009)

Use of the anti HER-2/neu antibody Herceptin in the treatment of human breast cancer: biological rationale and clinical results
por: Slamon, DJ
Publicado: (2000)

Surgical management of the breast and axilla after neoadjuvant treatment: the role of sentinel node biopsy
por: Mamounas, EP
Publicado: (2009)

Controversies in hormonal adjuvant therapy for premenopausal patients
por: Howell, A
Publicado: (2009)

Controversies in the hormonal adjuvant therapy of postmenopausal patients
por: Dowsett, M
Publicado: (2009)

Role of HER2 in local relapse and metastasis
por: Ménard, S
Publicado: (2005)

Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer
por: Baselga, J, et al.
Publicado: (2011)

Ultrasound elastography as an adjuvant to conventional ultrasound in the preoperative assessment of axillary lymph nodes in suspected breast cancer: a pilot study
por: Taylor, K, et al.
Publicado: (2010)

Monophosphoryl Lipid a as an adjuvant for immune therapy? A detailed in vitro comparison to LPS
por: Schülke, Stefan, et al.
Publicado: (2014)

The EGF receptor family as targets for breast cancer therapy
por: Baselga, J
Publicado: (2000)

Predicting response/resistance to endocrine therapy for breast cancer
por: Miller, WR, et al.
Publicado: (2005)

Targeting the cell cycle for prognosis and therapy of breast cancer
por: Keyomarsi, K, et al.
Publicado: (2005)

Targeting new therapies in combination with hormonal therapies for ER-positive breast cancer
por: Dowsett, M
Publicado: (2005)

Rationale for adjuvant measures in musculoskeletal diseases
por: Gast, Ulf
Publicado: (2013)

Combined hormonal therapy for advanced breast cancer in postmenopausal patients
por: Langecker, P, et al.
Publicado: (2003)

Tumour-selective transcriptional targeting for breast cancer gene therapy
por: Hurst, HC
Publicado: (2000)

Radically resected node-negative squamous cell carcinoma of thoracic esophagus: recurrence pattern and indication for adjuvant therapy
por: Fang, W, et al.
Publicado: (2013)

Differentiation therapy: targeting breast cancer stem cells to reduce resistance to radiotherapy and chemotherapy
por: Roy, R, et al.
Publicado: (2010)

Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial.
por: Ahmed, Nabil, et al.
Publicado: (2015)

Translational breast cancer research in luminal breast cancer
por: Dowsett, M
Publicado: (2011)

Molecular distinctions among ERBB2-overexpressing breast cancers
por: Jeffrey, SS
Publicado: (2005)

Epigenetics of breast cancer
por: Esteller, M
Publicado: (2011)

Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting?
por: Boyd, Kathleen A, et al.
Publicado: (2011)

Stem cells in normal breast development and breast cancer
por: Wicha, MS, et al.
Publicado: (2003)

Long-term survival of interval breast cancers in breast cancer screening in Wales
por: Fong, YF, et al.
Publicado: (2012)

Regulation of recombinational repair by the familial breast cancer susceptibility protein BRCA2
por: West, SC, et al.
Publicado: (2006)

Update on breast cancer genetics
por: Izatt, L
Publicado: (2006)

Clinical breast cancer and estrogen
por: Chew, HK
Publicado: (2003)

Predictive factors in breast cancer
por: Klijn, J, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_lpg63t7999ob7hg5f2hmgr9u9s